⚡Our October issue is live! Featuring new research in #glioblastoma, #breastcancer, #myocardialinfarction, #obesity, #UPFs, #GLP1 drugs, #bispecifics, #AI- and #proteomics-based diagnostics, and much more including Review, News & Opinion. Read it here: nature.com/nm/volumes/31/iss…

In a meta-analysis of 48 randomized trials of chronic kidney disease progression, reduction in the 6-month urinary albumin:creatinine ratio was associated with lower hazard ratios of established kidney disease endpoints, supporting the use of albuminuria change as a surrogate endpoint in clinical trials for chronic kidney disease. nature.com/articles/s41591-0…

A new study expands the utility of the gold-standard ferret model to assess risks associated with consuming raw milk and cheese contaminated with #influenzaA virus — marking an important step toward improving risk assessments in #publichealth. News & Views from Taronna Maines, Jessica Belser @CDCgov nature.com/articles/s41591-0…

In a follow up study presenting 96 week results, cabotegravir and rilpivirine long-acting therapy is still non-inferior to oral therapy for HIV, had acceptable safety and tolerability profiles, resulted in durable virologic suppression and provides further evidence that this should be considered for African treatment programs. nature.com/articles/s41591-0…

In cognitively normal older adults at risk for Alzheimer’s dementia, physical inactivity was associated with faster tau protein buildup and cognitive decline nature.com/articles/s41591-0… @WendyYau01 @HarvardAging @MGHNeurology

The first-in-human trial of AAV2i8-I1c (AB-1002) suggests a cautious return of #cardiac #genetherapy after earlier setbacks, with a new target, dose optimization and improved vector design shaping future directions. News & Views from Oliver Müller & colleagues @dzhk_germany nature.com/articles/s41591-0…

⭐Research highlight: Creativity enhances #brainhealth by improving connectivity in age-vulnerable regions, highlighting the importance of supporting creative activities in public health strategies. @NatureComms nature.com/articles/d41591-0…

⭐Research highlight: Baby wraps treated with the insecticide permethrin reduced the incidence of #malaria in infants by 66%, according to a randomized controlled trial in Uganda. @NEJM nature.com/articles/d41591-0…

A world-first! 🏳️‍⚧️🧬Our new study, the first #transhealth original research in @NatureMedicine shows how gender-affirming hormones reshape the body’s proteins to align with gender identity. nature.com/articles/s41591-0… #GenderAffirmingCare #transgender #TransResearch @UniMelbMDHS

Now at #ESMO25: In the phase 2/3 AGITG DYNAMIC-III trial, post-surgery ctDNA was prognostic but de-escalated chemotherapy in patients with ctDNA-negative stage III colon cancer did not meet non-inferiority for 3 year recurrence-free survival nature.com/articles/s41591-0…

Now at #ESMO25: In patients with locally advanced or metastatic solid tumors, treatment with a first in class inhibitor of the Hippo-YAP-TEAD pathway was safe and led to encouraging clinical response rates in patients with mesothelioma nature.com/articles/s41591-0…

Now at #ESMO25: In a phase 2 trial, first-line treatment of patients with advanced gastric cancer, GEJ cancer or esophageal adenocarcinoma with anti-TIGIT + anti-PD-1 + FOLFOX led to encouraging objective response rates and survival outcomes nature.com/articles/s41591-0…

Now at #ESMO25: In the phase 2 IKF/AIO PHERFLOT trial, perioperative FLOT + anti-PD-1 + anti-HER2 led to a pathological complete response rate of 48.4% in patients with resectable HER2+ esophagogastric adenocarcinoma @JosephTintelnot nature.com/articles/s41591-0…

Now at #ESMO25: in the phase 3 RELATIVITY-098 trial, nivolumab + relatlimab did not significantly change recurrence free survival for patients with stage III/IV resected melanoma, and the absence of tumor infiltrating LAG3+ T cells may play a role. nature.com/articles/s41591-0…

A new study provides physiological insights into the dying process, which could have substantial implications for resuscitation science, death determination and organ donation. Read the News & Views from Michael Rubin and Matthew Kirschen @PennMedicine @UTSWMedCenter nature.com/articles/s41591-0…

Delighted to be at #WHS2025 in Berlin. Tomorrow, the @NatureMedicine Commission on Quality Health Information for All will official launch at @WorldHealthSmt Our aim is to provide a framework for innovative solutions to advance quality health information equitably and for all

In @NatureMedicine, Caleb Rhodes (@PennMedicine), @HollyLynchez (@PennMEHP/ @PennCarey_Law) & @reshmagar (@YaleMed) outline strategies to help strengthen the integrity of @US_FDA drug approval decisions nature.com/articles/s41591-0…

Semaglutide or tirzepatide should be first-line medication treatment for people living with obesity and complications, according to the new EASO framework for the pharmacological treatment of obesity and its complications published in @NatureMedicine easo.org/semaglutide-and-tir…

Lots of great AI content in Nature Medicine this month! 🧠 @THBoussard on the fragile intelligence of ChatGPT — why we must tread carefully with generative AI in healthcare. 🩺 Our editorial urges more support for the human in the loop to build trustworthy AI. 🔗 nature.com/articles/s41591-0… 🔗 nature.com/articles/s41591-0… #AI #MedTech #HumanInTheLoop #NatureMedicine @NatureMedicine

Three studies that leverage blood-based gene expression data identify molecular and cellular host response signatures in #sepsis and critical illnesses, opening a pathway to mechanism-anchored #precisiontherapy. News & Views from Robert Stevens and Carl Harris @HopkinsMedicine nature.com/articles/s41591-0…